Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Echocardiographic Detection of Cardiotoxicity Using the Ventripoint (VMS) 3D AI Echocardiography System Versus Conventional Echo Analyses and Cardiac MRI in Patients Receiving Chemotherapy

NCT07093918 is registered in ClinicalTrials.gov with The Royal Wolverhampton Hospitals NHS Trust as lead sponsor.

NCT NCT07093918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Echocardiographic Detection of Cardiotoxicity Using the Ventripoint (VMS) 3D AI Echocardiography System Versus Conventional Echo Analyses and Cardiac MRI in Patients Receiving Chemotherapy
Lead sponsor
The Royal Wolverhampton Hospitals NHS Trust
Phase
Observational
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
November 30, 2030
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity